NCT05528458View on ClinicalTrials.gov

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2029

Conditions
Lung Adenocarcinoma
Interventions
DRUG

Osimertinib 80Mg Tab

Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection

Trial Locations (1)

06351

RECRUITING

Sehoon Lee, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER